MA27713A1 - Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases - Google Patents

Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases

Info

Publication number
MA27713A1
MA27713A1 MA28457A MA28457A MA27713A1 MA 27713 A1 MA27713 A1 MA 27713A1 MA 28457 A MA28457 A MA 28457A MA 28457 A MA28457 A MA 28457A MA 27713 A1 MA27713 A1 MA 27713A1
Authority
MA
Morocco
Prior art keywords
compounds
inhibitors
protein
aminoheteroarylic
kinases
Prior art date
Application number
MA28457A
Other languages
English (en)
Inventor
Jingjong Jean Cui
Dilip Bhumralkar
Iriny Botrous
Ji Yu Chu
Lee A Funk
Cathleen Elizabeth Hanau
Jr G Davis Harris
Lei Jia
Joanne Johnson
Pei-Pei Kung
Stephen A Kolodziej
Xiaoyuan Sharon Li
Jason Qishen Lin
Jerry Jialun Meng
Mitchell David Nambu
Christopher G Nelson
Mason Alan Pairish
Hong Shen
Michelle Tran-Dube
Allison Walter
Fang-Jie Zhang
Jennifer Zhang
Original Assignee
Fang-Jie Zhang
Jennifer Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32930516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fang-Jie Zhang, Jennifer Zhang filed Critical Fang-Jie Zhang
Publication of MA27713A1 publication Critical patent/MA27713A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

DEPOSANT Société dite : SUGEN, INC. REVENDICATION DE PRIORITES US 26 Février 2003 60/449,588 US 29 Janvier 2004 60/540,229 Composés aminohétéroaryliques servant d'inhibiteurs de protéine-kinases Des aminopyridines et aminopyrazines de formule (I), des compositions comprenant ces composés et des méthodes d'utilisation sont proposés. Les composés préférés de formule (I) ont une activité d'inhibiteurs de protéine-kinases, y compris comme inhibiteurs de c-MET.
MA28457A 2003-02-26 2005-08-26 Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases MA27713A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44958803P 2003-02-26 2003-02-26
US54022904P 2004-01-29 2004-01-29

Publications (1)

Publication Number Publication Date
MA27713A1 true MA27713A1 (fr) 2006-01-02

Family

ID=32930516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28457A MA27713A1 (fr) 2003-02-26 2005-08-26 Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases

Country Status (29)

Country Link
US (2) US7230098B2 (fr)
EP (2) EP1603570B9 (fr)
JP (1) JP4695588B2 (fr)
KR (1) KR101106905B1 (fr)
CN (1) CN103265477B (fr)
AP (1) AP2114A (fr)
AU (1) AU2004215428B2 (fr)
BR (1) BRPI0407827B8 (fr)
CA (1) CA2517256C (fr)
CY (2) CY1113837T1 (fr)
DK (2) DK1603570T5 (fr)
EA (1) EA010727B1 (fr)
EC (1) ECSP055988A (fr)
ES (2) ES2502490T3 (fr)
GE (1) GEP20084341B (fr)
HR (1) HRP20050714B1 (fr)
IL (1) IL170291A (fr)
IS (1) IS2910B (fr)
MA (1) MA27713A1 (fr)
ME (1) MEP52808A (fr)
MX (1) MXPA05009063A (fr)
NO (1) NO332188B1 (fr)
NZ (1) NZ541861A (fr)
OA (1) OA13151A (fr)
PL (1) PL216368B1 (fr)
PT (2) PT2476667E (fr)
RS (1) RS53118B (fr)
TN (1) TNSN05208A1 (fr)
WO (1) WO2004076412A2 (fr)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
WO2005082411A1 (fr) * 2004-02-23 2005-09-09 Sugen, Inc. Methode de traitement d'une croissance cellulaire anormale au moyen d'inhibiteurs c-met et m-tor
KR100799534B1 (ko) 2004-02-27 2008-01-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(1)
WO2005095386A1 (fr) * 2004-03-30 2005-10-13 Chiron Corporation Derives du thiophene substitues en tant qu'agents anticancereux
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CA2561628C (fr) * 2004-04-01 2012-05-08 Eli Lilly And Company Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
EP1784400B1 (fr) * 2004-08-23 2015-01-14 Eli Lilly And Company Agents récepteurs de l'histamine h3, préparation et utilisations thérapeutiques
CA2577937C (fr) * 2004-08-26 2010-12-21 Pfizer Inc. Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
KR20080072105A (ko) * 2004-08-26 2008-08-05 화이자 인코포레이티드 단백질 티로신 키나제 저해제 중간체의 제조를 위한거울상이성질선택적 생물학적 전환
EP1786777A1 (fr) * 2004-08-26 2007-05-23 Pfizer, Inc. Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
CN101193635A (zh) * 2005-05-13 2008-06-04 莱西肯医药有限公司 多环化合物及其使用方法
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TWI377198B (en) * 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
PT1963302E (pt) * 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
DE602006018354D1 (de) * 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
KR20090007347A (ko) * 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ATE535520T1 (de) 2006-08-23 2011-12-15 Eisai R&D Man Co Ltd Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
US7790885B2 (en) * 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
WO2008042867A2 (fr) * 2006-09-29 2008-04-10 Emiliem Inc. Modulateurs de kinases multiples
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
CA2672167C (fr) 2006-12-14 2016-01-26 Bayer Schering Pharma Aktiengesellschaft Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
CA2675755C (fr) * 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine et derives de pyridazine en tant qu'inhibiteurs de kinase
EP2123627B1 (fr) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Procédé de production d'amine aromatique ayant un groupe aralkyloxy ou hétéroaralkyloxy
CA2683559C (fr) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methodes de traitement d'un cancer resistant a des agents therapeutiques anti-erbb
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
MX2010001020A (es) * 2007-07-26 2010-03-01 Novartis Ag Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
KR101586503B1 (ko) 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
EP2215084B1 (fr) * 2007-10-23 2016-09-28 Allergan, Inc. Lactames substitués à usage thérapeutique
EP2215066A1 (fr) * 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Dérivés d'amide comme modulateurs de sirtuines
JP2011503066A (ja) * 2007-11-08 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド 可溶化チアゾロピリジン誘導体
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
WO2009073224A1 (fr) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Procédés de traitement de certaines maladies à l'aide de dérivés de la pyrimidine
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
WO2009096198A1 (fr) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations Nouveau derive de biaryle
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JPWO2009104520A1 (ja) * 2008-02-18 2011-06-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法（２）
WO2009111644A2 (fr) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions et procédés pour diagnostiquer et traiter le cancer du pancréas
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
FR2928923B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
WO2009151800A1 (fr) * 2008-05-07 2009-12-17 Merck & Co., Inc. Inhibiteurs d’époxyde hydrolase solubles, compositions contenant de tels composés et procédés de traitement
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
KR101691640B1 (ko) * 2008-06-19 2016-12-30 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
EP2321433A2 (fr) * 2008-08-29 2011-05-18 F. Hoffmann-La Roche AG Diagnostics et traitements des tumeurs vegf-independantes.
WO2010046780A2 (fr) * 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
EP2356116A1 (fr) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
US8367679B2 (en) * 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
JP2012102018A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc アミド化合物
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
CA2796967C (fr) * 2010-05-04 2015-12-01 Pfizer Inc. Derives heterocycliques destines au traitement de maladies
WO2011143423A2 (fr) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Composés utilisables en tant qu'inhibiteurs de la kinase atr
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
EP2625176B1 (fr) 2010-10-08 2016-08-17 Xcovery Holding Company LLC Composés substitués de 6-amino-pyridazin-3-yle carboxamide comme modulateurs de protéine kinases
WO2012074951A1 (fr) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Inhibiteurs de kinase macrocycliques
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CA2824970C (fr) 2011-02-11 2016-05-03 Batmark Limited Element inhalateur
CA2826892A1 (fr) * 2011-02-24 2012-08-30 Jiangsu Hansoh Pharmaceutical Co., Ltd. Composes contenant du phosphore en tant qu'inhibiteurs de la proteine kinase
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
WO2012178125A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés inhibiteurs de la kinase atr
CA2842841C (fr) * 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Molecules spirocycliques convenant comme inhibiteurs de proteines kinases
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
CA2863892C (fr) 2012-03-06 2016-08-30 Pfizer Inc. Derives macrocycliques pour le traitement de maladies proliferatives
WO2013136170A1 (fr) 2012-03-16 2013-09-19 Purdue Pharma L.P. Pyridines substituées en tant que bloqueurs des canaux sodiques
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
EP2836216B1 (fr) * 2012-04-13 2022-06-08 Epizyme, Inc. Polythérapie anticancéreuse
CN103387535B (zh) * 2012-05-10 2016-06-01 广东东阳光药业有限公司 取代的炔基吡啶化合物及其使用方法和用途
WO2013177092A1 (fr) * 2012-05-23 2013-11-28 Sunshine Lake Pharma Co., Ltd. Composés d'alcynylpyridine substitués et procédés d'utilisation
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014046730A1 (fr) 2012-09-24 2014-03-27 Ventana Medical Systems, Inc. Méthode d'identification d'un cancer du poumon autre qu'à petites cellules (nsclc) réagissant à un traitement au moyen de la kinase du lymphome anaplasique (alk) comme marqueur
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
WO2014081816A1 (fr) * 2012-11-21 2014-05-30 Concert Pharmaceuticals, Inc. Dérivés fluorés de composés amino-hétéroaryle substitués par pyrazole
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2935257B1 (fr) 2012-12-20 2018-02-07 Purdue Pharma LP Sulfonamides cycliques en tant que bloquants des canaux sodiques
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
AU2014211856C1 (en) * 2013-02-02 2018-04-12 Centaurus Biopharma Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
WO2014143240A1 (fr) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CA2912219C (fr) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarqueurs pour predire et evaluer la reponse de sujets atteints de cancer de l'endometre a des composes a base de lenvatinib
WO2015034729A1 (fr) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Composés de pyridine substituée et leurs méthodes d'utilisation
WO2015036898A2 (fr) * 2013-09-10 2015-03-19 Shilpa Medicare Limited Nouveaux sels de crizotinib et leur préparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
AU2013402175B2 (en) 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
EP3066118B1 (fr) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps anti-alk, conjugues, et recepteurs antigeniques chimeriques, et leur utilisation
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CA2934251C (fr) 2013-12-20 2024-01-02 3-V Biosciences, Inc. Combinaison de modulateurs heterocycliques de synthese des lipides et medicaments chimiotherapeutiques dans le traitement du cancer
CN103755627B (zh) * 2014-01-09 2016-02-17 定陶县友帮化工有限公司 2-氨基-3-羟基-5-氯吡啶的合成方法
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015167825A1 (fr) 2014-04-29 2015-11-05 Emory University Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés
WO2015172747A1 (fr) * 2014-05-16 2015-11-19 Zhaoyin Wang Molécules spirocycliques servant d'inhibiteurs de mth1
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016019909A1 (fr) * 2014-08-07 2016-02-11 江苏豪森药业股份有限公司 Nouvelle forme cristalline de composé anticancéreux, procédé de préparation et utilisation correspondants
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
EP3187491A4 (fr) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. Dérivé de quinoline de pureté élevée et son procédé de fabrication
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
EP3215150B1 (fr) 2014-11-07 2022-07-20 The Regents of The University of Michigan Inhibiteurs de la transcription de gènes médiée par le facteur apparenté à la myocardine et le facteur de réponse sérique (mrtf/srf) et procédés pour les utiliser
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3246046A4 (fr) 2015-01-13 2018-12-05 Kyoto University Agent pour la prévention et/ou le traitement de la sclérose latérale amyotrophique
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
US10405627B2 (en) * 2015-07-14 2019-09-10 Michael Charles Boland, III Luggage with fold out table
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
US11129808B2 (en) 2016-03-15 2021-09-28 University Of South Florida PKC-delta-I inhibitor formulations and uses thereof
WO2017180723A1 (fr) 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Inhibiteurs de l'atr (ataxia telangiectasia and rad3 related) et leurs méthodes d'utilisation
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US10933068B2 (en) * 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
EP3558992A4 (fr) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. Activateur de canaux trek (canaux k+ associés à twik)
CN106866627B (zh) * 2017-01-24 2021-09-14 南方医科大学 3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (fr) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CA3070073A1 (fr) 2017-07-18 2019-01-24 Nuvation Bio Inc. Composes de 1,8-naphthyridinone et leurs utilisations
WO2019018570A1 (fr) 2017-07-19 2019-01-24 Ignyta, Inc. Compositions pharmaceutiques contenant de l'entrectinib
WO2019077506A1 (fr) 2017-10-17 2019-04-25 Ignyta, Inc. Compositions pharmaceutiques et formes galéniques solides
CN107794282B (zh) * 2017-11-20 2020-12-25 浙江工业大学 一种克唑替尼手性中间体的制备方法及菌株
WO2019154665A1 (fr) * 2018-02-07 2019-08-15 Basf Se Nouveaux pyridine carboxamides
DK3749646T3 (da) * 2018-03-15 2022-05-02 Fujian Haixi Pharmaceuticals Co Ltd Heteroaryl-forbindelser som kinase-inhibitor
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
WO2019206049A1 (fr) * 2018-04-25 2019-10-31 Zhuhai Yufan Biotechnologies Co., Ltd Inhibiteurs d'hpk1, procédé de préparation et utilisation associés
CN110396087A (zh) * 2018-04-25 2019-11-01 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂、制备方法及其应用
CN108947895B (zh) * 2018-08-22 2021-09-24 肇庆中彩机电技术研发有限公司 一种抗癌活性的化合物
WO2020150674A1 (fr) * 2019-01-18 2020-07-23 Nuvation Bio Inc. Composés hétérocycliques en tant qu'antagonistes de l'adénosine
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CA3126704A1 (fr) * 2019-01-18 2020-07-23 Nuvation Bio Inc. Composes heterocycliques en tant qu'antagonistes de l'adenosine
WO2020191208A1 (fr) 2019-03-20 2020-09-24 Emory University Antagonistes du récepteur ep2 de la prostaglandine, dérivés, et utilisations associés
KR20220004206A (ko) 2019-05-14 2022-01-11 텔리진 엘티디. 키네이스 억제제로 유용한 치환된 거대고리화합물
CA3149796A1 (fr) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Agents anticancereux pour le traitement des cancers canins
KR102426921B1 (ko) * 2019-09-24 2022-07-29 주식회사 이노보테라퓨틱스 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
WO2021196655A1 (fr) * 2020-04-03 2021-10-07 中国药科大学 Composé contenant une structure benzimidazole, son procédé de préparation et application de celui-ci
CN113493437B (zh) * 2020-04-03 2022-07-26 中国药科大学 含苯并咪唑结构的化合物及其制备方法和用途
WO2023086671A1 (fr) * 2021-11-15 2023-05-19 The Broad Institute, Inc. Composés, compositions et méthodes pour induire une activité intracellulaire antimicrobienne et pour prévenir et traiter des infections microbiennes
CN119451699A (zh) 2022-07-04 2025-02-14 中外制药株式会社 并用药物
TW202425998A (zh) 2022-08-30 2024-07-01 日商中外製藥股份有限公司 併用醫藥
CN120166992A (zh) * 2022-10-31 2025-06-17 上海皓元医药股份有限公司 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法
WO2026071043A1 (fr) * 2024-09-30 2026-04-02 Alivexis, Inc. Inhibiteurs de kit, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
EP0654024A1 (fr) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) et disulfures associes (seleniures) inhibant les tyrosine kinases et presentant des proprietes antitumorales
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5521190A (en) * 1993-05-27 1996-05-28 Fmc Corporation Insecticidal pterdines and 8-deazapteridines
JPH07109260A (ja) * 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (fr) 1995-04-20 2001-07-24 Pfizer Inc. Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0923585B1 (fr) 1996-07-18 2002-05-08 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
EP0922030A1 (fr) 1996-08-23 1999-06-16 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
SE9700661D0 (sv) * 1997-02-25 1997-02-25 Astra Ab New compounds
CA2289102A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
CA2291709A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
EP1206265B1 (fr) * 1999-06-30 2003-11-12 Merck & Co., Inc. Composes inhibiteurs de la src kinase
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
ATE307121T1 (de) 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
BR0112265A (pt) 2000-07-07 2003-06-24 Tufts College Compostos de tetraciclina substituìda, e de sanciclina 7-substituìda, método para tratar um estado responsivo à tetraciclina em um indivìduo, e, composição farmacêutica
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
SK11322003A3 (en) * 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
DE60234269D1 (de) 2001-11-21 2009-12-17 Pharmacia & Upjohn Co Llc Substituierte aryl 1,4-pyrazin derivate
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
CA2577937C (fr) 2004-08-26 2010-12-21 Pfizer Inc. Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
DK1603570T5 (da) 2013-12-09
BRPI0407827A (pt) 2006-02-14
RS53118B (sr) 2014-06-30
US7230098B2 (en) 2007-06-12
EP2476667B1 (fr) 2014-07-16
PL378759A1 (pl) 2006-05-15
GEP20084341B (en) 2008-03-25
IS7990A (is) 2005-08-18
CN103265477B (zh) 2017-01-11
BRPI0407827B1 (pt) 2020-01-07
EP1603570A2 (fr) 2005-12-14
JP4695588B2 (ja) 2011-06-08
NZ541861A (en) 2009-05-31
US20070072874A1 (en) 2007-03-29
ES2401330T3 (es) 2013-04-18
PT2476667E (pt) 2014-09-18
DK2476667T3 (da) 2014-09-15
KR20050111604A (ko) 2005-11-25
US8106197B2 (en) 2012-01-31
ES2502490T3 (es) 2014-10-03
CA2517256C (fr) 2013-04-30
AP2005003383A0 (en) 2005-09-30
KR101106905B1 (ko) 2012-01-25
OA13151A (en) 2006-12-13
CA2517256A1 (fr) 2004-09-10
JP2006519232A (ja) 2006-08-24
DK1603570T3 (da) 2013-05-21
NO20054080L (no) 2005-11-21
EP1603570B9 (fr) 2013-10-23
PT1603570E (pt) 2013-03-26
TNSN05208A1 (fr) 2007-06-11
IL170291A (en) 2012-08-30
AP2114A (en) 2010-03-04
EA200501236A1 (ru) 2006-04-28
WO2004076412A2 (fr) 2004-09-10
NO20054080D0 (no) 2005-09-01
EP2476667A2 (fr) 2012-07-18
MXPA05009063A (es) 2005-12-12
CY1115472T1 (el) 2017-01-04
IS2910B (is) 2014-11-15
EP1603570B1 (fr) 2013-01-23
NO332188B1 (no) 2012-07-23
EP2476667A3 (fr) 2013-01-02
CY1113837T1 (el) 2016-07-27
MEP52808A (en) 2011-05-10
RS20050708A (sr) 2007-06-04
WO2004076412A3 (fr) 2004-12-29
US20050009840A1 (en) 2005-01-13
ECSP055988A (es) 2006-01-16
HRP20050714A2 (en) 2006-03-31
HRP20050714B1 (hr) 2016-07-15
CN103265477A (zh) 2013-08-28
EA010727B1 (ru) 2008-10-30
PL216368B1 (pl) 2014-03-31
AU2004215428B2 (en) 2009-08-27
EP1603570A4 (fr) 2008-05-21
AU2004215428A1 (en) 2004-09-10
BRPI0407827B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TNSN05208A1 (fr) Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases
MA30076B1 (fr) Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
EP1675552A4 (fr) Preparation d'azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases
DE59812455D1 (de) Fluorpyrazol-biphenylamide als fungizide
NO20034289L (no) N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren
WO2004063151A3 (fr) Nouveaux inhibiteurs de tyrosine kinase
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1854789A4 (fr) Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
WO2004067703A3 (fr) Antagonistes 5ht7 et agonistes inverses
TNSN03090A1 (fr) Derives d'ethers phenyliques d'heterocyclyle servant d' inhibiteurs selectifs de reabsorption de serotonine
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
UA80474C2 (en) Aminoheteroaryl compounds as inhibitors of protein kinase
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
ATE274515T1 (de) Pyrazolopyridinderivate